INTERCEPT PHARMACEUTICALS INC 4
4 · INTERCEPT PHARMACEUTICALS INC · Filed Feb 3, 2017
Insider Transaction Report
Form 4
McMinn Rachel
Chief Strategy Officer
Transactions
- Award
Common Stock
2017-02-01+5,000→ 17,916 total - Award
Option to Purchase Common Stock
2017-02-01+8,300→ 8,300 totalExercise: $107.18Exp: 2027-02-01→ Common Stock (8,300 underlying)
Footnotes (2)
- [F1]25% of the shares of restricted stock will vest on January 1, 2018, subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the "2012 Plan"). The remaining shares of restricted stock will vest pro rata on every subsequent three-month anniversary of the initial vesting date through January 1, 2021 (representing the vesting on each such vesting date of 6.25% of the shares of restricted stock), subject to the terms and conditions of the award and the 2012 Plan.
- [F2]25% of the shares of common stock underlying this option will vest on January 1, 2018, subject to the terms and conditions of the award and the 2012 Plan. The remainder of the shares of common stock underlying this option will vest pro rata on a monthly basis after the initial vesting date through January 1, 2021 (representing the vesting on each such vesting date of approximately 2.0833% of the shares of common stock initially underlying this option), subject to the terms and conditions of the award and the 2012 Plan.